TrialCell reports. Medicine2021

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes.

Rune V Overgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.